[Kombipek in the therapy of patients with broncho-obstructive lung diseases]

Bronchodilator combipek of Russian produce was tested in 43 patients with bronchial asthma of various severity. Combipek contains 200 mg of theophylline and 8 mg of salbutamol. Pharmacokinetics of the drug was evaluated after a single administration and upon obtaining equilibrium concentration. Functional and clinical evidence showed a prolonged effect and safety of the drug in long-term treatment of bronchial asthma. Adverse effects emerged in 13 (30.2%) patients. They were typical for theophylline and beta 2-adrenostimulators. Combipek is advocated as a treatment of choice in patients with nocturnal asphyxia, in those who can hardly tolerate large doses of theophylline and beta 2-adrenostimulators.